Business Description
Interpace Biosciences Inc
NAICS : 541380
SIC : 8099
ISIN : US46062X2045
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.24 | |||||
Equity-to-Asset | -4.55 | |||||
Debt-to-Equity | -0.14 | |||||
Debt-to-EBITDA | 1.65 | |||||
Interest Coverage | 4.96 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | -23.07 | |||||
Beneish M-Score | -2.6 | |||||
WACC vs ROIC |
Growth Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 4.6 | |||||
3-Year Book Growth Rate | -25.5 |
Momentum Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 54.98 | |||||
9-Day RSI | 54.57 | |||||
14-Day RSI | 54.53 | |||||
6-1 Month Momentum % | -21.67 | |||||
12-1 Month Momentum % | 10.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.53 | |||||
Quick Ratio | 0.47 | |||||
Cash Ratio | 0.11 | |||||
Days Inventory | 25.13 | |||||
Days Sales Outstanding | 46.51 | |||||
Days Payable | 32.94 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | 57.24 |
Profitability Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 59.01 | |||||
Operating Margin % | 10.64 | |||||
Net Margin % | 6.73 | |||||
FCF Margin % | 7.37 | |||||
ROE % | Neg. Equity | |||||
ROA % | 20.53 | |||||
ROIC % | 54.42 | |||||
3-Year ROIIC % | -108.27 | |||||
ROC (Joel Greenblatt) % | 144.32 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 1.99 | |||||
PE Ratio without NRI | 1.91 | |||||
Price-to-Owner-Earnings | 2.94 | |||||
PS Ratio | 0.16 | |||||
Price-to-Free-Cash-Flow | 2.2 | |||||
Price-to-Operating-Cash-Flow | 1.9 | |||||
EV-to-EBIT | 3.28 | |||||
EV-to-EBITDA | 2.52 | |||||
EV-to-Revenue | 0.31 | |||||
EV-to-Forward-Revenue | 0.44 | |||||
EV-to-FCF | 4.39 | |||||
Earnings Yield (Greenblatt) % | 30.49 | |||||
FCF Yield % | 45.1 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:IDXG
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Interpace Biosciences Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 41.676 | ||
EPS (TTM) ($) | 0.78 | ||
Beta | 0.5 | ||
Volatility % | 64.53 | ||
14-Day RSI | 54.53 | ||
14-Day ATR ($) | 0.113285 | ||
20-Day SMA ($) | 1.506075 | ||
12-1 Month Momentum % | 10.83 | ||
52-Week Range ($) | 0.78 - 2.6 | ||
Shares Outstanding (Mil) | 4.39 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Interpace Biosciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Interpace Biosciences Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Interpace Biosciences Inc Frequently Asked Questions
What is Interpace Biosciences Inc(IDXG)'s stock price today?
When is next earnings date of Interpace Biosciences Inc(IDXG)?
Does Interpace Biosciences Inc(IDXG) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |